One Course of Adjuvant BEP in Clinical Stage I Nonseminoma Mature and Expanded Results from the SWENOTECA group.

T Tandstad; Olof Ståhl; Ulf Håkansson; O Dahl; H S Haugnes; O H Klepp; C W Langberg; A Laurell; J Oldenburg; A Solberg; K Söderström; Eva Cavallin-Ståhl; U Stierner; R Wahlquist; N Wall; G Cohn-Cedermark

doi:10.1093/annonc/mdu375

One Course of Adjuvant BEP in Clinical Stage I Nonseminoma Mature and Expanded Results from the SWENOTECA group.

T Tandstad, Olof Ståhl, Ulf Håkansson, O Dahl, H S Haugnes, O H Klepp, C W Langberg, A Laurell, J Oldenburg, A Solberg, K Söderström, Eva Cavallin-Ståhl, U Stierner, R Wahlquist, N Wall, G Cohn-Cedermark

Research output: Contribution to journal › Article › peer-review

Abstract

SWENOTECA has since 1998 offered patients with clinical stage I (CS I) nonseminoma, adjuvant chemotherapy with one course of bleomycin, etoposide and cisplatin (BEP). The aim has been to reduce the risk of relapse, sparing patients the need of toxic salvage treatment. Initial results on 312 patients treated with one course of adjuvant BEP, with a median follow-up of 4.5 years, have been previously published. We now report mature and expanded results.

Original language	English
Pages (from-to)	2167-2172
Journal	Annals of Oncology
Volume	25
Issue number	11
DOIs	https://doi.org/10.1093/annonc/mdu375
Publication status	Published - 2014

Bibliographical note

The information about affiliations in this record was updated in December 2015.
The record was previously connected to the following departments: Molecular Reproductive Medicine (013241710), Oncology, MV (013035000), Pediatrics/Urology/Gynecology/Endocrinology (013240400)

Subject classification (UKÄ)

Cancer and Oncology

Access to Document

10.1093/annonc/mdu375

http://www.ncbi.nlm.nih.gov/pubmed/25114021?dopt=Abstract

Cite this

Tandstad, T., Ståhl, O., Håkansson, U., Dahl, O., Haugnes, H. S., Klepp, O. H., Langberg, C. W., Laurell, A., Oldenburg, J., Solberg, A., Söderström, K., Cavallin-Ståhl, E., Stierner, U., Wahlquist, R., Wall, N., & Cohn-Cedermark, G. (2014). One Course of Adjuvant BEP in Clinical Stage I Nonseminoma Mature and Expanded Results from the SWENOTECA group. Annals of Oncology, 25(11), 2167-2172. https://doi.org/10.1093/annonc/mdu375

@article{f69f4c56faa04731bfaed084e78b6a5d,

title = "One Course of Adjuvant BEP in Clinical Stage I Nonseminoma Mature and Expanded Results from the SWENOTECA group.",

abstract = "SWENOTECA has since 1998 offered patients with clinical stage I (CS I) nonseminoma, adjuvant chemotherapy with one course of bleomycin, etoposide and cisplatin (BEP). The aim has been to reduce the risk of relapse, sparing patients the need of toxic salvage treatment. Initial results on 312 patients treated with one course of adjuvant BEP, with a median follow-up of 4.5 years, have been previously published. We now report mature and expanded results.",

author = "T Tandstad and Olof St{\aa}hl and Ulf H{\aa}kansson and O Dahl and Haugnes, {H S} and Klepp, {O H} and Langberg, {C W} and A Laurell and J Oldenburg and A Solberg and K S{\"o}derstr{\"o}m and Eva Cavallin-St{\aa}hl and U Stierner and R Wahlquist and N Wall and G Cohn-Cedermark",

note = "The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Molecular Reproductive Medicine (013241710), Oncology, MV (013035000), Pediatrics/Urology/Gynecology/Endocrinology (013240400)",

year = "2014",

doi = "10.1093/annonc/mdu375",

language = "English",

volume = "25",

pages = "2167--2172",

journal = "Annals of Oncology",

issn = "1569-8041",

publisher = "Oxford University Press",

number = "11",

}

Tandstad, T, Ståhl, O, Håkansson, U, Dahl, O, Haugnes, HS, Klepp, OH, Langberg, CW, Laurell, A, Oldenburg, J, Solberg, A, Söderström, K, Cavallin-Ståhl, E, Stierner, U, Wahlquist, R, Wall, N & Cohn-Cedermark, G 2014, 'One Course of Adjuvant BEP in Clinical Stage I Nonseminoma Mature and Expanded Results from the SWENOTECA group.', Annals of Oncology, vol. 25, no. 11, pp. 2167-2172. https://doi.org/10.1093/annonc/mdu375

TY - JOUR

T1 - One Course of Adjuvant BEP in Clinical Stage I Nonseminoma Mature and Expanded Results from the SWENOTECA group.

AU - Tandstad, T

AU - Ståhl, Olof

AU - Håkansson, Ulf

AU - Dahl, O

AU - Haugnes, H S

AU - Klepp, O H

AU - Langberg, C W

AU - Laurell, A

AU - Oldenburg, J

AU - Solberg, A

AU - Söderström, K

AU - Cavallin-Ståhl, Eva

AU - Stierner, U

AU - Wahlquist, R

AU - Wall, N

AU - Cohn-Cedermark, G

N1 - The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Molecular Reproductive Medicine (013241710), Oncology, MV (013035000), Pediatrics/Urology/Gynecology/Endocrinology (013240400)

PY - 2014

Y1 - 2014

N2 - SWENOTECA has since 1998 offered patients with clinical stage I (CS I) nonseminoma, adjuvant chemotherapy with one course of bleomycin, etoposide and cisplatin (BEP). The aim has been to reduce the risk of relapse, sparing patients the need of toxic salvage treatment. Initial results on 312 patients treated with one course of adjuvant BEP, with a median follow-up of 4.5 years, have been previously published. We now report mature and expanded results.

AB - SWENOTECA has since 1998 offered patients with clinical stage I (CS I) nonseminoma, adjuvant chemotherapy with one course of bleomycin, etoposide and cisplatin (BEP). The aim has been to reduce the risk of relapse, sparing patients the need of toxic salvage treatment. Initial results on 312 patients treated with one course of adjuvant BEP, with a median follow-up of 4.5 years, have been previously published. We now report mature and expanded results.

U2 - 10.1093/annonc/mdu375

DO - 10.1093/annonc/mdu375

M3 - Article

C2 - 25114021

SN - 1569-8041

VL - 25

SP - 2167

EP - 2172

JO - Annals of Oncology

JF - Annals of Oncology

IS - 11

ER -

One Course of Adjuvant BEP in Clinical Stage I Nonseminoma Mature and Expanded Results from the SWENOTECA group.

Abstract

Bibliographical note

Subject classification (UKÄ)

Access to Document

Fingerprint

Cite this